Isomorphic Labs raises $5 billion to push AI-designed drugs toward trials
The London-based Alphabet spinout led by Demis Hassabis has now raised more than $7.7 billion. It has not yet put a drug into clinical trials.
Key takeaways
- Isomorphic Labs raised $5 billion in a Series C co-led by Greenoaks and Sequoia, six months after a $2.1 billion round.
- The company has now raised more than $7.7 billion in total, pharmaphorum reports; its valuation was not disclosed.
- Isomorphic says the money will fund its IsoDDE drug design engine and push its first candidates toward clinical trials.
- Isomorphic has no drug in clinical trials yet, though it reports positive preclinical results.
- It works with Eli Lilly, Novartis and Johnson & Johnson.
Isomorphic Labs, the AI drug-discovery company spun out of Google DeepMind, has closed a $5 billion Series C round, it said on Tuesday, Nov. 17, according to TechCrunch, Tech.eu, The Decoder and pharmaphorum. The round was co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining as a new investor.
Existing backers also took part, including Alphabet and its venture arms GV and CapitalG, Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund, TechCrunch and pharmaphorum report. The round comes about six months after a $2.1 billion Series B in May, and takes the London-based company's total funding to more than $7.7 billion, pharmaphorum says.
Isomorphic did not disclose its valuation, TechCrunch reports. Bloomberg reported earlier this month that the company was seeking a $50 billion valuation, according to TechCrunch, and pharmaphorum puts its value at an estimated $50 billion.
What will the money be used for?
The company says it will keep developing its drug design engine, IsoDDE, build more advanced biology models and push its first drug candidates toward clinical trials, according to Tech.eu and pharmaphorum. It says part of the money will support AI development and clinical development infrastructure, Tech.eu reports.
Isomorphic's work builds on DeepMind's AlphaFold, TechCrunch reports; its IsoDDE engine uses a set of AI models to predict protein structures and how they interact with potential drugs, pharmaphorum says. Isomorphic says its platform has produced "positive preclinical results" in cancer and immune disorders, both in its own programmes and with partners, according to TechCrunch and pharmaphorum. It has research deals with Eli Lilly, Novartis and Johnson & Johnson.
What has it not done yet?
Isomorphic has not yet moved any drug candidates into clinical trials, pharmaphorum notes, and The Decoder points out that it has no approved drug. The size of the investment reflects strong investor appetite for AI companies, pharmaphorum says.
"This round enables us to accelerate our progress," said Demis Hassabis, Isomorphic's founder and chief executive, according to Tech.eu and pharmaphorum.
Hassabis, who shared the 2024 Nobel Prize in Chemistry for AlphaFold, stepped back from running DeepMind this year. He moved into a chairman role at DeepMind, TechCrunch reports, and The Decoder says he stepped down from day-to-day leadership in August 2026 and is now Alphabet's chief scientist. This is Isomorphic's first fundraise since that change, TechCrunch reports.
Questions readers are asking
What is Isomorphic Labs?
A London-based AI drug-discovery company spun out of Google DeepMind in 2021 and led by Demis Hassabis. It uses AI models to design potential medicines.
Who invested in the round?
Greenoaks and Sequoia Capital co-led it, with Andreessen Horowitz as a new investor and existing backers including Alphabet, GV, CapitalG, Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund.
Does Isomorphic have any approved drugs?
No. It has not yet moved a drug candidate into clinical trials; it says the new money will help it get there.
Sources
- TechCrunch: Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials
- Tech.eu: Sequoia and Greenoaks lead massive $5BN Series C funding round in Isomorphic Labs
- pharmaphorum: Isomorphic Labs raises $5bn in massive third round
- The Decoder: Isomorphic Labs raises $5 billion in its second mega-round within six months
- #isomorphic-labs
- #funding
- #drug-discovery
- #deepmind
- #startups
Get the day's top AI & tech stories on WhatsApp: Follow the NextFish channel
Get stories like this every morning.
Related
AI Startups2 min
Boltz raises $110 million for AI models that design drug molecules
The MIT spinout's Series A was led by Bessemer Venture Partners. It says six of the world's 20 largest pharma companies use its platform.
Chips & Infra2 min
UK government funds back AI chip startup Fractile in £500m-plus round
Sovereign AI and the British Business Bank joined Fractile's Series C, which the government says values the inference chip designer at over £5 billion.